About the Endocannabinoid System in the Human Body
Source: US National Institutes of Health
“In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.”
Endocannabinoids and Phytocannabinoids
Endocannabinoids created within the human regulate the correct physiological functions of the body called homeostasis. Phytocannabinoids found in Cannabis plants are a perfect supplement to the body’s own endocannabinoids and thus are helping to balance and stabilize the physiological functions.
CBDium THC free – our 100% natural dietary supplement – contains, among other beneficial substances like minerals, vitamins, flavonoids terpenes and others, various cannabinoids and therefore is suitable as a supplement for endocannabinoids within the human endocannabinoid system.
Studies According to the Implied Benefits of CBD
Shannon S., Opila-Lehman J.: Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report.
The Permanente Journal 2016 Fall; 20(4): 108-111
Jones, N. A., Hill A. J., Smith I., Bevan S. A., Williams C. M., Whalley B. J., and Stephens G. J.: Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Journal of Pharmacology and Experimental Therapeutics, 2010 Feb; 332(2): 569–577
Rock E.M., Bolognin D., Limebeer C.L., Anavi-Goffer S., Fletcher P.J., Mechoulam R., Pertwee R.G., and Parker L.A.: Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
British Journal of Pharmacology, 2012 Apr; 165(8): 2620–2634
Hayakawa K., Mishima K., Irie K., Mishima S., Fujioka M., Orito K., Egashira N., Katsurabayashi S., Takasaki K., Iwasaki K., and Fujiwara M.: Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism
Neuropharmacology, Volume 55, Issue 8, December 2008, pp. 1280-1286
Booz G.W.: Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress
Free Radical Biology and Medicine, Volume 51, Issue 5, 1 September 2011, pp. 1054-1061
Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M., and Izzo A.A.: Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells
Journal of Neurochemistry, Volume 89, Issue 1, February 2004, pp. 134–141
Vaccani A., Massi P., Colombo A., Rubino T., and Parolaro D.: Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
British Journal of Pharmacology, 2005 Apr; 144(8): 1032–1036
Zuardi A.W., Crippa J.A., Hallak J.E., Bhattacharyya S., Atakan Z., Martin-Santos R., McGuire P.K., and Guimarães F.S.: A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
Current Pharmaceutical Design, 2012; 18(32): 5131-40
Hussain S.A., Zhou R., Jacobson C., Weng J., Cheng E., Lay J., Hung P., Lerner J.T., and Sankar R.: Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome
Epilepsy & Behavior, Volume 47, June 2015, pp. 138-141
Napimoga M.H., Benatti B.B., Limac F.O., Alvesa P.M., Camposc C.S., Pena-dos-Santos D.R., Severino F.P., Cunha F.Q., Guimarães F.S.: Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats
International Immunopharmacology, Volume 9, Issue 2, February 2009, pp. 216-222
X.-H. Lin, B. Yuece, Y.-Y. Li, Y.-J. Feng, J.-Y. Feng, L.-Y. Yu, K. Li, Y.-N. Li, M. Storr: A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents
Neurogastroenterology & Motility, Volume 23, Issue 9, September 2011, pp. 862–e342
Iuvone T., Esposito G., De Filippis D., Scuderi C., and Steardo Luca: Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
CNS Neuroscience & Therapeutics, Volume 15, Issue 1, Spring 2009, pp. 65–75